| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $27.6M | — | +24.8% |
| SG&A Expense | $16.2M | — | +3.1% |
| Operating Income | -$43.8M | — | -15.8% |
| Net Income | -$41.3M | — | -15.0% |
| EPS (Basic) | -$0.37 | — | +11.9% |
| EPS (Diluted) | -$0.37 | — | +11.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $229.1M | +1.1% | +283.4% |
| Short-term Investments | $50.6M | -43.9% | -64.9% |
| Current Assets | $285.0M | -11.9% | +31.9% |
| Total Assets | $293.6M | -11.7% | +33.7% |
| Current Liabilities | $16.0M | -29.6% | -11.0% |
| Total Liabilities | $20.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$36.9M | — | +7.4% |
| Capital Expenditures | $11K | — | +0.0% |
| Investing Cash Flow | $36.3M | — | +183.1% |
| Financing Cash Flow | $3.2M | — | -95.1% |
| Free Cash Flow | -$36.9M | — | +7.4% |
| +12.0% |
| Stockholders' Equity | $273.2M | -10.5% | +35.6% |